Clinical trials
Phase 2 Multiple Myeloma trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
63 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 44 |
| Active, not recruiting | 6 |
| Terminated | 6 |
| Recruiting | 4 |
| Unknown status | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 8 |
| Universitätsklinikum Hamburg-Eppendorf | 5 |
| Celgene | 4 |
| Janssen-Cilag International NV | 4 |
| Novartis Pharmaceuticals | 4 |
| Arbeitsgemeinschaft medikamentoese Tumortherapie | 3 |
| GlaxoSmithKline | 3 |
| Genzyme, a Sanofi Company | 2 |
| Hoffmann-La Roche | 2 |
| Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 63 |
| Recurrence | 10 |
| Lymphoma, Non-Hodgkin | 5 |
| Neoplasms | 5 |
| Hodgkin Disease | 4 |
| Blast Crisis | 2 |
| Bone Marrow Neoplasms | 2 |
| Burkitt Lymphoma | 2 |
| Leukemia, Hairy Cell | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
Trials
Showing 1 to 25 of 63. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.